The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria
Open accessAbstract
Purpose: Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating gastrointestinal stromal tumors (GISTs) treated with imatinib. This study evaluates whether computed tomography (CT) findings of GIST after imatinib treatment correlate with tumor responses by [18 F]fluorodeoxyglucose (FDG) positron emission tomography (PET) and develops reliable, quantitative, CT response criteria. Patients and Methods: A total of 172 lesions selected by RECIST were evaluated in 40 patients with metastatic GISTs treated with imatinib. All patients had pretreatment and 2-month follow-up CTs and FDG-PETs. Multivariate analysis was performed using tumor size and density (Hounsfield unit [HU]) on CT and maximum standardized uptake value (SUV max) on FDG-PET. Patients were observed up to 28 months. Results: Mean baseline tumor size and density on CT were 5.3 cm and 72.8 HU, respectively, and mean baseline SUV max on FDG-PET was 5.8. Thirty-three patients had good response on FDG-PET. A decrease in tumor size of more than 10% or a decrease in tumor density of more than 15% on CT had a sensitivity of 97% and a specificity of 100% in identifying PET responders versus 52% and 100% by RECIST. Good responders on CT at 2 months had significantly longer time to progression than those who did not respond (P = .01). Conclusion: Small changes in tumor size or density on CT are sensitive and specific methods of assessing the response of GISTs. If the prognostic value of our proposed CT response criteria can be confirmed prospectively, the criteria should be employed in future studies of patients with GIST.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,720
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Ratain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., Gore, M., Desai, A. A., Patnaik, A., Xiong, H. Q., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6723 · Cited by 1,032
Stroobants, S., Goeminne, J., Seegers, M., Dimitrijevic, S., Dupont, P., Nuyts, J., Martens, M., van den Borne, B., Cole, P., Sciot, R., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00073-x · Cited by 526
Choi, H., Charnsangavej, C., Faria, S. D. C., Tamm, E. P., Benjamin, R. S., Johnson, M. M., Macapinlac, H. A., & Podoloff, D. A. (2004) · American Journal of Roentgenology · doi:10.2214/ajr.183.6.01831619 · Cited by 459
Self-citationPietras, K., Östman, A., SJÖQUIST, M., Buchdunger, E., Reed, R. K., Heldin, C., & Rubin, K. (2001) · PubMed · Cited by 450
Cited by
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
“Additional anatomic characteristics of GIST, such as the development of mural nodules, but not necessarily with tumor growth because of the predominantly cystic nature of the tumors, are indicative of progression and of a poor outcome (48,49).”
BackgroundInfluentialNCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
Demetri, G. D., von Mehren, M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., Maki, R. G., Pisters, P. W. T., Raut, C. P., Riedel, R. F., Schuetze, S., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0116 · Cited by 1,219
Imaging biomarker roadmap for cancer studies
O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.162 · Cited by 1,091
Gastrointestinal stromal tumour
Rubin, B. P., Heinrich, M. C., & Corless, C. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60780-6 · Cited by 1,036
Gastrointestinal stromal tumours: origin and molecular oncology
Corless, C. L., Barnett, C. M., & Heinrich, M. C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3143 · Cited by 891
Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 779
Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy095 · Cited by 750
Gastrointestinal stromal tumour
Joensuu, H., Hohenberger, P., & Corless, C. L. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60106-3 · Cited by 703
Demetri, G. D., Benjamin, R. S., Blanke, C. D., Blay, J.-Y., Casali, P., Choi, H., Corless, C. L., Debiec-Rychter, M., DeMatteo, R. P., Ettinger, D. S., et al. (2007) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2007.2002 · Cited by 634
Self-citationCasali, P. G., Blay, J. Y., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.005 · Cited by 605
Chawla, S., Henshaw, R., Seeger, L., Choy, E., Blay, J.-Y., Ferrari, S., Kroep, J., Grimer, R., Reichardt, P., Rutkowski, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70277-8 · Cited by 587
Adam, R., De Gramont, A., Figueras, J., Guthrie, A., Kokudo, N., Kunstlinger, F., Loyer, E., Poston, G., Rougier, P., Rubbia-Brandt, L., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0121 · Cited by 583
We Should Desist Using RECIST, at Least in GIST
Benjamin, R. S., Choi, H., Macapinlac, H. A., Burgess, M. A., Patel, S. R., Chen, L. L., Podoloff, D. A., & Charnsangavej, C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3411 · Cited by 559
Self-citationIntravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Breitbach, C. J., Burke, J., Jonker, D., Stephenson, J., Haas, A. R., Chow, L. Q. M., Nieva, J., Hwang, T.-H., Moon, A., Patt, R., et al. (2011) · Nature · doi:10.1038/nature10358 · Cited by 551
Park, B.-H., Hwang, T., Liu, T.-C., Sze, D. Y., Kim, J.-S., Kwon, H.-C., Oh, S. Y., Han, S.-Y., Yoon, J.-H., Hong, S.-H., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70107-4 · Cited by 521
Gronchi, A., Ferrari, S., Quagliuolo, V., Broto, J. M., Pousa, A. L., Grignani, G., Basso, U., Blay, J.-Y., Tendero, O., Beveridge, R. D., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30334-0 · Cited by 496
Nishida, T., Blay, J.-Y., Hirota, S., Kitagawa, Y., & Kang, Y.-K. (2016) · Gastric Cancer · doi:10.1007/s10120-015-0526-8 · Cited by 486
Casali, P. G., & Blay, J.-Y. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq208 · Cited by 480
Sorafenib for Advanced and Refractory Desmoid Tumors
Gounder, M. M., Mahoney, M. R., Van Tine, B. A., Ravi, V., Attia, S., Deshpande, H. A., Gupta, A. A., Milhem, M. M., Conry, R. M., Movva, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805052 · Cited by 463
Gastrointestinal stromal tumours
Blay, J.-Y., Kang, Y.-K., Nishida, T., & von Mehren, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00254-5 · Cited by 460
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402
Wilky, B. A., Trucco, M. M., Subhawong, T. K., Florou, V., Park, W., Kwon, D., Wieder, E. D., Kolonias, D., Rosenberg, A. E., Kerr, D. A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30153-6 · Cited by 392
Nishino, M., Jagannathan, J. P., Ramaiya, N. H., & Van den Abbeele, A. D. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.09.4110 · Cited by 378
Goh, V., Ganeshan, B., Nathan, P., Juttla, J. K., Vinayan, A., & Miles, K. A. (2011) · Radiology · doi:10.1148/radiol.11110264 · Cited by 367
Grignani, G., Palmerini, E., Ferraresi, V., D'Ambrosio, L., Bertulli, R., Asaftei, S. D., Tamburini, A., Pignochino, Y., Sangiolo, D., Marchesi, E., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71136-2 · Cited by 340
Selection for hepatic resection of colorectal liver metastases: expert consensus statement
Adams, R. B., Aloia, T. A., Loyer, E., Pawlik, T. M., Taouli, B., & Vauthey, J. (2013) · HPB · doi:10.1111/j.1477-2574.2012.00557.x · Cited by 331
George, S., Merriam, P., Maki, R. G., Van den Abbeele, A. D., Yap, J. T., Akhurst, T., Harmon, D. C., Bhuchar, G., O'Mara, M. M., D'Adamo, D. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9890 · Cited by 321
Drug rechallenge and treatment beyond progression—implications for drug resistance
Kuczynski, E. A., Sargent, D. J., Grothey, A., & Kerbel, R. S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.158 · Cited by 286
(2012) · Annals of Oncology · doi:10.1093/annonc/mds252 · Cited by 281
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria
Tirkes, T., Hollar, M. A., Tann, M., Kohli, M. D., Akisik, F., & Sandrasegaran, K. (2013) · RadioGraphics · doi:10.1148/rg.335125214 · Cited by 279
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
(2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 276
Phase II Study of Imatinib in Advanced Chordoma
Stacchiotti, S., Longhi, A., Ferraresi, V., Grignani, G., Comandone, A., Stupp, R., Bertuzzi, A., Tamborini, E., Pilotti, S., Messina, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.3656 · Cited by 276
Gronchi, A., Palmerini, E., Quagliuolo, V., Martin Broto, J., Lopez Pousa, A., Grignani, G., Brunello, A., Blay, J.-Y., Tendero, O., Diaz Beveridge, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03289 · Cited by 263
Patterns of Response and Progression to Immunotherapy
Borcoman, E., Nandikolla, A., Long, G., Goel, S., & Le Tourneau, C. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200643 · Cited by 262
Park, M. S., Patel, S. R., Ludwig, J. A., Trent, J. C., Conrad, C. A., Lazar, A. J., Wang, W., Boonsirikamchai, P., Choi, H., Wang, X., et al. (2011) · Cancer · doi:10.1002/cncr.26098 · Cited by 261
Self-citationMeyer, M., Ronald, J., Vernuccio, F., Nelson, R. C., Ramirez-Giraldo, J. C., Solomon, J., Patel, B. N., Samei, E., & Marin, D. (2019) · Radiology · doi:10.1148/radiol.2019190928 · Cited by 258
Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis
Gounder, M. M., Lefkowitz, R. A., Keohan, M. L., D'Adamo, D. R., Hameed, M., Antonescu, C. R., Singer, S., Stout, K., Ahn, L., & Maki, R. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3322 · Cited by 255
William, W. N., Pataer, A., Kalhor, N., Correa, A. M., Rice, D. C., Wistuba, I. I., Heymach, J., Lee, J. J., Kim, E. S., Munden, R., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182774108 · Cited by 138
Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy
Weissferdt, A., Pataer, A., Vaporciyan, A. A., Correa, A. M., Sepesi, B., Moran, C. A., Wistuba, I. I., Roth, J. A., Shewale, J. B., Heymach, J. V., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.11.003 · Cited by 113
Lu, L., Dercle, L., Zhao, B., & Schwartz, L. H. (2021) · Nature Communications · doi:10.1038/s41467-021-26990-6 · Cited by 104
Chen, J., Wang, C., Han, J., Luan, Y., Cui, Y., Shen, R., Sha, D., Cong, L., Zhang, Z., & Wang, W. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.45 · Cited by 37
Metadata
- Authors
- Choi, H., Charnsangavej, C., Faria, S. C., Macapinlac, H. A., Burgess, M. A., Patel, S. R., Chen, L. L., Podoloff, D. A., & Benjamin, R. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-05-01
- Volume
- 25
- Issue
- 13
- Pages
- 1753-1759
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2123534406
- Cited by
- 1,520
- References
- 14
- FWCI
- 61.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.